Glucose 20% Labesfal

Glucose 20% Labesfal is an intravenous solution containing 20% w/v glucose as the active ingredient. It is supplied in a sterile liquid form intended for infusion into the bloodstream. The product is manufactured for the European Union market and is used as a source of carbohydrate energy in clinical settings where rapid glucose delivery is required.

Glucose 20% Labesfal is employed in various medical situations where a quick increase in blood glucose is needed. It is commonly used for: - Treating hypoglycemia in patients unable to take oral glucose. - Providing caloric support during surgery or intensive care. - Serving as a carrier for other intravenous medications. - Maintaining fluid and electrolyte balance in patients receiving parenteral nutrition. - Supporting patients with metabolic disorders that require controlled glucose administration.

Glucose 20% Labesfal may cause a range of reactions, most of which are related to its osmolarity and carbohydrate content.

Common: - Mild hyperglycemia (elevated blood sugar levels). - Local irritation at the infusion site. - Nausea or vomiting. - Headache. - Transient electrolyte shifts, such as low potassium.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hyperosmolar hyperglycemic state (HHS) in susceptible individuals. - Allergic reaction or anaphylaxis (rare). - Fluid overload, especially in patients with cardiac or renal impairment.

When using Glucose 20% Labesfal, clinicians should consider several safety measures. Important precautions include: - Assessing baseline blood glucose and electrolyte levels before infusion. - Monitoring blood glucose frequently during and after administration. - Adjusting infusion rates in patients with diabetes, renal insufficiency, or heart failure. - Avoiding rapid infusion in neonates and infants due to risk of hyperosmolar injury. - Ensuring proper aseptic technique to prevent contamination. - Verifying compatibility with other IV solutions or medications before co‑administration.

Glucose 20% Labesfal can interact with other agents, influencing its safety and efficacy. Interaction considerations are:

Avoid: - Co‑administration with high‑dose insulin without close glucose monitoring. - Simultaneous infusion of other hyperosmolar solutions that may exacerbate fluid overload.

Use with caution: - Concurrent use of diuretics, which may affect electrolyte balance. - Medications that alter glucose metabolism, such as corticosteroids or beta‑agonists. - Intravenous potassium supplements, due to risk of shifting potassium levels. - Drugs that require a specific pH environment, as glucose solutions can affect pH.